XML 49 R39.htm IDEA: XBRL DOCUMENT
v3.20.2

INVESTMENTS - RELATED PARTIES (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract] |
Schedule of investments | Investments in AVLP and Alzamend Neuro, Inc. (“Alzamend”) at June 30, 2020 and December 31, 2019, are comprised of the following:
| June 30, |  | December 31,
| 2020 |  | 2019
Investment in convertible promissory note of AVLP | $ 9,802,686 |  | $ 9,595,079
Accrued interest in convertible promissory note of AVLP | 2,025,475 |  | 2,025,475
Total investment in convertible promissory note of AVLP – Gross | 11,828,161 |  | 11,620,554
Less: provision for loan losses | (5,088,927) |  | (5,079,834)
Total investment in convertible promissory note of AVLP | $ 6,739,234 |  | $ 6,540,720
Investment in derivative instruments of AVLP | 858,564 |  | 1,330,684
Investment in common stock of AVLP | 169,860 |  | 238,602
Investment in common stock of Alzamend | 575,925 |  | 558,938
Investment in derivative instruments and common stock of AVLP and Alzamend | $ 1,604,349 |  | $ 2,128,224
Total investment in AVLP and Alzamend – Net | $ 8,343,583 |  | $ 8,668,944
Investment in warrants and common stock of AVLP and Alzamend | $ 1,604,349 |  | $ 2,128,224
Investment in convertible promissory note of AVLP | 6,739,234 |  | 6,540,720
Total investment in AVLP and Alzamend – Net | $ 8,343,583 |  | $ 8,668,944
Schedule of summarizes the changes in our investments | The following table summarizes the changes in our investments in AVLP and Alzamend during the six months ended June 30, 2020:
|  | Investment in |  |  |  |
|  | warrants and |  | Investment in |  | Total
|  | common stock |  | convertible |  | investment
|  | of AVLP and |  | promissory |  | in AVLP and
|  | Alzamend |  | note of AVLP |  | Alzamend – Net
Balance at January 1, 2020 |  | $ 2,128,224 |  | $ 6,540,720 |  | $ 8,668,944
Investment in convertible promissory notes of AVLP |  | — |  | 198,514 |  | 198,514
Investment in common stock of AVLP and Alzamend |  | 12,884 |  | — |  | 12,884
Fair value of derivative instruments issued by AVLP |  | 9,093 |  | — |  | 9,093
Unrealized loss in derivative instruments of AVLP |  | (481,213) |  | — |  | (481,213)
Unrealized loss in common stock of AVLP and Alzamend |  | (64,639) |  | — |  | (64,639)
Balance at June 30, 2020 |  | $ 1,604,349 |  | $ 6,739,234 |  | $ 8,343,583

X
- Definition Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments. + References No definition available. + Details
Name: | us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the summary of investment holdings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-12C) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010 + Details
Name: | us-gaap_SummaryInvestmentHoldingsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration